Healthcare provider profile · identity verified

Yaolen Bolanos, MD

Internal Medicine · PEMBROKE PINES, FL · NPI 1942402045

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	273	107
Vitamin D2	Ergocalciferol (Vitamin D2)	226	64
Losartan Potassium	Losartan Potassium	219	86
Metformin Hcl	Metformin Hcl	193	72
Amlodipine Besylate	Amlodipine Besylate	179	73
Simvastatin	Simvastatin	156	60
Levothyroxine Sodium	Levothyroxine Sodium	124	45
Albuterol Sulfate Hfa	Albuterol Sulfate	100	37
Lisinopril	Lisinopril	100	36
Gabapentin	Gabapentin	78	36
Nifedipine Er	Nifedipine	78	23
Pantoprazole Sodium	Pantoprazole Sodium	77	36
Prednisone	Prednisone	76	58
Meloxicam	Meloxicam	75	43
Omeprazole	Omeprazole	71	39
Metoprolol Tartrate	Metoprolol Tartrate	69	28
Alprazolam	Alprazolam	68	15
Xarelto	Rivaroxaban	66	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	65	29
Glipizide	Glipizide	64	30
Tramadol Hcl	Tramadol Hcl	62	16
Metoprolol Succinate	Metoprolol Succinate	61	25
Tamsulosin Hcl	Tamsulosin Hcl	59	22
Clopidogrel	Clopidogrel Bisulfate	55	23
Carvedilol	Carvedilol	53	21
Hydrochlorothiazide	Hydrochlorothiazide	53	21
Rosuvastatin Calcium	Rosuvastatin Calcium	52	21
Trazodone Hcl	Trazodone Hcl	51	23
Alendronate Sodium	Alendronate Sodium	48	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	47	suppressed
Furosemide	Furosemide	46	18
Baclofen	Baclofen	45	27
Diclofenac Sodium	Diclofenac Sodium	45	15
Farxiga	Dapagliflozin Propanediol	44	suppressed
Famotidine	Famotidine	43	26
Latanoprost	Latanoprost	42	suppressed
Azithromycin	Azithromycin	41	37
Eliquis	Apixaban	39	suppressed
Buspirone Hcl	Buspirone Hcl	36	15
Ciprofloxacin Hcl	Ciprofloxacin Hcl	36	32
Donepezil Hcl	Donepezil Hcl	36	18
Fluticasone Propionate	Fluticasone Propionate	36	19
Novolog Flexpen	Insulin Aspart	35	suppressed
Temazepam	Temazepam	33	suppressed
Ciclopirox	Ciclopirox	32	suppressed
Montelukast Sodium	Montelukast Sodium	31	13
Tradjenta	Linagliptin	31	suppressed
Tresiba Flextouch U-100	Insulin Degludec	31	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	30	14
Mirtazapine	Mirtazapine	30	suppressed
Ezetimibe	Ezetimibe	29	11
Jardiance	Empagliflozin	29	suppressed
Meclizine Hcl	Meclizine Hcl	28	16
Spironolactone	Spironolactone	28	suppressed
Ciclopirox	Ciclopirox Olamine	26	suppressed
Lumigan	Bimatoprost	26	suppressed
Sertraline Hcl	Sertraline Hcl	26	12
Enalapril Maleate	Enalapril Maleate	25	suppressed
Timolol Maleate	Timolol Maleate	25	suppressed
Ammonium Lactate	Ammonium Lactate	24	suppressed
Ketoconazole	Ketoconazole	24	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	24	suppressed
Memantine Hcl	Memantine Hcl	24	11
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	24	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	24	suppressed
Clonazepam	Clonazepam	23	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	22	12
Doxycycline Hyclate	Doxycycline Hyclate	22	21
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	22	suppressed
Ibuprofen	Ibuprofen	21	16
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	21	suppressed
Sucralfate	Sucralfate	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	11
Ozempic	Semaglutide	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Fenofibrate	Fenofibrate	19	suppressed
Linzess	Linaclotide	19	suppressed
Lorazepam	Lorazepam	19	suppressed
Amoxicillin	Amoxicillin	18	15
Cephalexin	Cephalexin	18	15
Folic Acid	Folic Acid	18	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	18	suppressed
Valsartan	Valsartan	18	suppressed
Betamethasone Valerate	Betamethasone Valerate	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	16	suppressed
Lactulose	Lactulose	16	suppressed
Glimepiride	Glimepiride	15	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	15	14
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Chlordiazepoxide Hcl	Chlordiazepoxide Hcl	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	14	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	14	suppressed
Fluconazole	Fluconazole	14	11
Hydrocortisone	Hydrocortisone	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Levofloxacin	Levofloxacin	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Benzonatate	Benzonatate	12	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	12	suppressed
Finasteride	Finasteride	12	suppressed
Fluocinonide	Fluocinonide	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Trueplus Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Allopurinol	Allopurinol	11	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Methotrexate	Methotrexate Sodium	11	suppressed
Pravastatin Sodium	Pravastatin Sodium	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error